САЩ - английски - NLM (National Library of Medicine)

a-s medication solutions - dimethyl fumarate (unii: fo2303mni2) (monomethyl fumarate - unii:45iub1px8r) - dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. dimethyl fumarate delayed-release capsules are contraindicated in patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of dimethyl fumarate delayed-release capsules. reactions have included anaphylaxis and angioedema [see warnings and precautions ( 5.1)]. risk summary   there are no adequate data on the developmental risk associated with the use of dimethyl fumarate delayed-release capsules in pregnant women. in animals, adverse effects on offspring survival, growth, sexual maturation, and neurobehavioral function were observed when dimethyl fumarate (dmf) was administered during pregnancy and lactation at clinically relevant doses [see data] .  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown.  data   animal data in rats administered dmf orally (25, 100, 250 mg/kg/day) throughout organogenesis, embryofetal toxicity (reduced fetal body weight and delayed ossification) were observed at the highest dose tested. this dose also produced evidence of maternal toxicity (reduced body weight). plasma exposure (auc) for monomethyl fumarate (mmf), the major circulating metabolite, at the no-effect dose is approximately three times that in humans at the recommended human dose (rhd) of 480 mg/day. in rabbits administered dmf orally (25, 75, and 150 mg/kg/day) throughout organogenesis, embryolethality and decreased maternal body weight were observed at the highest dose tested. the plasma auc for mmf at the no-effect dose is approximately 5 times that in humans at the rhd.  oral administration of dmf (25, 100, and 250 mg/kg/day) to rats throughout organogenesis and lactation resulted in increased lethality, persistent reductions in body weight, delayed sexual maturation (male and female pups), and reduced testicular weight at the highest dose tested. neurobehavioral impairment was observed at all doses. a no-effect dose for developmental toxicity was not identified. the lowest dose tested was associated with plasma auc for mmf lower than that in humans at the rhd. risk summary   there are no data on the presence of dmf or mmf in human milk. the effects on the breastfed infant and on milk production are unknown.  the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for dimethyl fumarate delayed-release capsules and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. clinical studies of dimethyl fumarate delayed-release capsules did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

САЩ - английски - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients:

САЩ - английски - NLM (National Library of Medicine)

mylan institutional inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 500 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - methylene blue, quantity: 50 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections

Австралия - английски - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 10 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Австралия - английски - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 20 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Австралия - английски - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 250 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Австралия - английски - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 1000 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Австралия - английски - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 100 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections

Австралия - английски - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - water for injections, quantity: 500 ml - injection, solvent for - excipient ingredients: - water for injections is used for the reconstitution and preparation of aqueous injections